Literature DB >> 29133657

Revisiting the "Tram-Track" sign.

Akshay Gopinathan Nair1, Veena R Iyer2, Indumati Gopinathan3.   

Abstract

Entities:  

Mesh:

Year:  2017        PMID: 29133657      PMCID: PMC5700599          DOI: 10.4103/ijo.IJO_510_17

Source DB:  PubMed          Journal:  Indian J Ophthalmol        ISSN: 0301-4738            Impact factor:   1.848


× No keyword cloud information.
A 55-year-old female presented with a 3-week-old history of sudden decrease in vision in the right eye. Visual acuity was 20/1200 (right eye) and 20/20 (left eye). A relative afferent pupillary defect, proptosis of 2 mm, and disc edema were noted in the right eye [Fig. 1a].
Figure 1

(a) Disc edema in the right eye. (b) Is a coronal, postcontrast fat-suppressed T1-weighted image showing enhancement and thickening of the right optic nerve sheath with the central nonenhancing nerve

(a) Disc edema in the right eye. (b) Is a coronal, postcontrast fat-suppressed T1-weighted image showing enhancement and thickening of the right optic nerve sheath with the central nonenhancing nerve On magnetic resonance imaging, T1-weighted [Fig. 1b] and fat-suppressed T2-weighted images [Fig. 2a and b] demonstrated irregular nodular thickening along the right optic nerve (arrows) with a T2-hypointense nodular deposit on the optic nerve sheath (arrow, 2B). Postcontrast fat-suppressed axial T1-weighted contiguous images [Fig. 2c and d] demonstrate irregular peripheral enhancement of the nodular region (arrow, 2C). In addition, marked enhancement and thickening of the right optic nerve sheath with the central nonenhancing nerve can be seen (arrow, 2D). While an optic nerve sheath meningioma was being considered as a likely diagnosis, a detailed systemic history gave a significant finding: the patient had a history of undergoing lumpectomy, chemotherapy, and radiation to the left breast, six years ago for invasive ductal carcinoma (T2N0M0). On examination, a firm lump was palpable in the left breast. On positron emission tomography imaging, “hot spots” were found in the left breast, liver, right orbit, and multiple bony sites. Percutaneous liver biopsy confirmed the diagnosis of metastatic breast cancer. A cerebrospinal fluid analysis was done subsequently, as requested by the treating oncologist, as a part of her systemic chemotherapy, which was positive for tumor cells. Therefore, this classic “tram-track” appearance [Fig. 2d] was due to leptomeningeal carcinomatosis from breast cancer.
Figure 2

(a and b) are axial T1-weighted and fat-suppressed T2-weighted images, respectively, which show irregular nodular thickening along the right optic nerve (arrows) with a T2-hypointense nodular deposit on the optic nerve sheath (arrow, 2b). Postcontrast fat-suppressed axial T1-weighted contiguous images through the orbit (c and d) demonstrate irregular peripheral enhancement of the nodular region (arrow, 2c). The classical tram-track appearance is seen in figure 2D (arrow)

(a and b) are axial T1-weighted and fat-suppressed T2-weighted images, respectively, which show irregular nodular thickening along the right optic nerve (arrows) with a T2-hypointense nodular deposit on the optic nerve sheath (arrow, 2b). Postcontrast fat-suppressed axial T1-weighted contiguous images through the orbit (c and d) demonstrate irregular peripheral enhancement of the nodular region (arrow, 2c). The classical tram-track appearance is seen in figure 2D (arrow) The optic nerve tram-track sign is most commonly seen in optic nerve sheath meningiomas, which typically cause segmental or circumferential enlargement of the optic nerve sheath. On contrast imaging, the nerve can be seen as an unenhanced central linear structure surrounded by the enhanced meningioma.[1] Other conditions which can present with a tram-track appearance of the optic nerve include inflammatory diseases such as demyelinating optic neuritis, sarcoidosis, idiopathic orbital inflammatory disease, perioptic hemorrhage, leukemic infiltration, Erdheim–Chester disease, and metastases.[23] Metastases from the breast to the optic nerve can mimic optic nerve sheath meningiomas.[45] Generally speaking, metastases of breast cancer account for the majority of ocular and orbital metastases; however, breast cancer metastasizing specifically to the optic nerve is uncommon, with only a handful of cases being reported.[6] Furthermore, recurrent breast cancer presenting as vision loss is decidedly rare and can exhibit the tram-track sign on imaging.[47]

Conclusion

Tram-track sign may be a radiological feature of optic nerve metastasis from breast cancer

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  7 in total

1.  The optic nerve tram-track sign.

Authors:  Uday S Kanamalla
Journal:  Radiology       Date:  2003-06       Impact factor: 11.105

2.  Carcinoma of the breast metastatic to the optic nerve mimicking an optic nerve sheath meningioma: case report and review of the literature.

Authors:  Benjamin Fox; Paulette Pacheco; Franco DeMonte
Journal:  Skull Base       Date:  2005-11

3.  CT evaluation of perineural orbital lesions: evaluation of the "tram-track" sign.

Authors:  T T Johns; C M Citrin; J Black; J L Sherman
Journal:  AJNR Am J Neuroradiol       Date:  1984 Sep-Oct       Impact factor: 3.825

4.  Carcinoma metastatic to the eye and orbit III. A clinicopathologic study of 28 cases metastatic to the orbit.

Authors:  R L Font; A P Ferry
Journal:  Cancer       Date:  1976-09       Impact factor: 6.860

5.  Optic nerve breast metastasis mimicking meningioma.

Authors:  O Backhouse; I Simmons; A Frank; A Cassels-Brown
Journal:  Aust N Z J Ophthalmol       Date:  1998-08

Review 6.  [Breast carcinoma metastasis to the optic nerve: case report and review of literature].

Authors:  V A Cherekaev; N V Lasunin; M A Stepanian; D L Rotin; N N Grigor'eva; E R Vetlova; N V Lobanova
Journal:  Zh Vopr Neirokhir Im N N Burdenko       Date:  2013

7.  Magnetic resonance imaging of optic nerve.

Authors:  Foram Gala
Journal:  Indian J Radiol Imaging       Date:  2015 Oct-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.